Work

PS5-09-27: A phase i/ii single-arm trial of azenosertib (zn-c3) combined with carboplatin and pembrolizumab in patients with metastatic triple-negative breast cancer (zap-it)

Year: 2026

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-09-27

Authors: F. Lynce, N. Tayob, N. Chen, A. Grinshpun, R. Davis, M. K. DeMeo, A. G. Waks, R. Nanda, J. L. Guerriero, G. Shapiro, S. M. Tolaney

Institutions: Dana-Farber Cancer Institute, University of Chicago, Hadassah Medical Center, Brigham and Women's Hospital

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129645129

FWCI:

Cites:

Cited by:

Related to: